Federal Register / Vol. 75, No. 185 / Friday, September 24, 2010 / Notices 58413 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Amended 

Notice of Meeting 

Notice is hereby given of a change in 

the meeting of the Center for Scientific 

Review Special Emphasis Panel, 

September 30, 2010, 8:30 a.m. to 

October 1, 2010, 5 p.m., National 

Institutes of Health, 6701 Rockledge 

Drive, Bethesda, MD 20892 which was 

published in the Federal Register on 

September 9, 2010, 75 FR 54896–54897. 

The meeting will be one day only 

September 30, 2010. The meeting time 

and location remain the same. The 

meeting is closed to the public. 

Dated: September 20, 2010. 

Jennifer S. Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2010–23954 Filed 9–23–10; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, Pilot 

Clinical Studies in Nephrology and Urology. 

Date: October 18, 2010. 

Time: 8 a.m. to 6 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892. 

(Virtual Meeting). 

Contact Person: Ryan G. Morris, PhD, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4205, 

MSC 7814, Bethesda, MD 20892. 301–435– 

1501. morrisr@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, Stem Cell 

and Developmental Biology. 

Date: October 25–26, 2010. 

Time: 11 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892. 

(Virtual Meeting). 

Contact Person: Noni Byrnes, PhD, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5130, 

MSC 7840, Bethesda, MD 20892. (301) 435– 

1023. byrnesn@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, 

Fellowships: Biophysical and Physiological 

Neuroscience. 

Date: November 8–9, 2010. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: The Willard InterContinental Hotel, 

1401 Pennsylvania Avenue, NW., 

Washington, DC 20004. 

Contact Person: Eugene Carstea, PhD, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5194, 

MSC 7846, Bethesda, MD 20892. (301) 408– 

9756. carsteae@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, Small 

Business: Biomedical Sensing, Measurement 

and Instrumentation [SSMI] (SBIR/STTR). 

Date: November 8, 2010. 

Time: 8 a.m. to 4 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hyatt Regency Bethesda, One 

Bethesda Metro Center, 7400 Wisconsin 

Avenue, Bethesda, MD 20814. 

Contact Person: Guo Feng Xu, PhD, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5122, 

MSC 7854, Bethesda, MD 20892. 301–435– 

1032. xuguofen@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, Fellowship: 

Biophysical and Biochemical Sciences. 

Date: November 8–9, 2010. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hyatt Regency Bethesda, One 

Bethesda Metro Center, 7400 Wisconsin 

Avenue, Bethesda, MD 20814. 

Contact Person: Alexander Gubin, PhD, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4196, 

MSC 7812, Bethesda, MD 20892. 301–435– 

2902. gubina@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, PAR09–160, 

161, 162: Cancer Health Disparities and 

Diversity in Basic Cancer Research. 

Date: November 9–10, 2010. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Beacon Hotel and Corporate 

Quarters, 1615 Rhode Island Avenue, NW., 

Washington, DC 20036. 

Contact Person: Cathleen L Cooper, PhD, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4208, 

MSC 7812, Bethesda, MD 20892. 301–443– 

4512. cooperc@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, PAR–10– 

082: Shared Instrumentation: Confocal 

Microscopy and Advanced Imaging. 

Date: November 9–10, 2010. 

Time: 8:30 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Amalfi Hotel, 20 West Kinzie Street, 

Chicago, IL 60654. 

Contact Person: Jonathan Arias, PhD, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5170, 

MSC 7840, Bethesda, MD 20892. 301–435– 

2406. ariasj@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, Small 

Business: Clinical Neurophysiology, Devices, 

Auditory Devices and Neuroprosthesis. 

Date: November 11–12, 2010. 

Time: 8 a.m. to 12 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: The Ritz-Carlton, Washington DC, 

1150 22nd Street, NW., Washington, DC 

20037. 

Contact Person: Keith Crutcher, PhD, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5207, 

MSC 7846, Bethesda, MD 20892. 301–435– 

1278. crutcherka@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, Small 

Business: Neuropharmacology. 

Date: November 11–12, 2010. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: The U.S. Grant Hotel, 326 

Broadway, San Diego, CA 92101. 

Contact Person: Aidan Hampson, PhD, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5199, 

MSC 7850, Bethesda, MD 20892. (301) 435– 

0634. hampsona@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, PA09–064: 

Seizure Mitigation through Continuous EEG 

with Responsive Vagus Nerve Stimulation. 

Date: November 12, 2010. 

Time: 12 p.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: The Ritz-Carlton, Washington DC, 

1150 22nd Street, NW., Washington, DC 

20037. 

Contact Person: Keith Crutcher, PhD, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5207, 

MSC 7846, Bethesda, MD 20892. 301–435– 

1278. crutcherka@csr.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 


srobinson on DSKHWCL6B1PROD with NOTICES
58414 Federal Register / Vol. 75, No. 185 / Friday, September 24, 2010 / Notices 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 

Dated: September 20, 2010. 

Jennifer S. Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2010–23952 Filed 9–23–10; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2010–N–0268] 

Dental Products Panel of the Medical 

Devices Advisory Committee; 

Amendment of Notice 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

The Food and Drug Administration 

(FDA) is announcing an amendment to 

the notice of meeting of the Dental 

Products Panel of the Medical Devices 

Advisory Committee. This meeting was 

announced in the Federal Register of 

June 11, 2010 (75 FR 33315). The 

amendment is being made to reflect a 

change in the Agenda portion of the 

document. There are no other changes. 

FOR FURTHER INFORMATION CONTACT: Olga 

I. Claudio, Food and Drug 

Administration, Center for Devices and 

Radiological Health, 10903 New 

Hampshire Ave., Bldg. 66, rm. 1553, 

Silver Spring, MD 20993–0002, 301– 

796–7608, or FDA Advisory Committee 

Information Line, 1–800–741–8138 

(301–443–0572 in the Washington DC 

area), code 3014512518. Please call the 

Information Line for up-to-date 

information on this meeting. 

SUPPLEMENTARY INFORMATION: In the 

Federal Register of June 11, 2010, FDA 

announced that a meeting of the Dental 

Products Panel of the Medical Devices 

Advisory Committee would be held on 

December 14 and 15, 2010. On page 

33316, in the first column, in the 

Agenda portion of the document, in the 

second full paragraph, in the second 

sentence, the phrase ‘‘(docket numbers 

FDA–2008–N–0163 and FDA–2009–P– 

0357)’’ is changed to read as follows: 

‘‘(docket numbers FDA–2008–N–0163, 

FDA–2009–P–0357, and FDA–2010–P– 

0056–0001)’’ 

This notice is issued under the 

Federal Advisory Committee Act (5 

U.S.C. app. 2) and 21 CFR part 14, 

relating to the advisory committees. 

Dated: September 21, 2010. 

Jill Hartzler Warner, 

Acting Associate Commissioner for Special 

Medical Programs. 

[FR Doc. 2010–23914 Filed 9–23–10; 8:45 am] 

BILLING CODE 4160–01–S 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Medicare & Medicaid 

Services 

[CMS–3240–N] 

Medicare Program; Meeting of the 

Medicare Evidence Development and 

Coverage Advisory Committee— 

November 17, 2010 

AGENCY: Centers for Medicare & 

Medicaid Services (CMS), HHS. 

ACTION: Notice of meeting. 

SUMMARY: This notice announces that a 

public meeting of the Medicare 

Evidence Development & Coverage 

Advisory Committee (MEDCAC) 

(‘‘Committee’’) will be held on 

Wednesday, November 17, 2010. The 

Committee generally provides advice 

and recommendations concerning the 

adequacy of scientific evidence needed 

to determine whether certain medical 

items and services can be covered under 

the Medicare statute. This meeting will 

focus on the currently available 

evidence regarding the clinical benefits 

and harms of on-label and off-label use 

of Autologous Cellular Immunotherapy 

Treatment of Metastatic Prostate Cancer. 

This meeting is open to the public in 

accordance with the Federal Advisory 

Committee Act (5 U.S.C. App. 2, section 

10(a)). 

DATES: Meeting Date: The public 

meeting will be held on Wednesday, 

November 17, 2010 from 7:30 a.m. until 

4:30 p.m., Eastern Standard Time (EST). 

Deadline for Submission of Written 

Comments: Written comments must be 

received at the address specified in the 

ADDRESSES section of this notice by 5 

p.m. EST, October 18, 2010. Once 

submitted, all comments are final. 

Deadlines for Speaker Registration 

and Presentation Materials: The 

deadline to register to be a speaker and 

to submit powerpoint presentation 

materials and writings that will be used 

in support of an oral presentation, is 5 

p.m., EST on Wednesday, October 18, 

2010. Speakers may register by phone or 

via e-mail by contacting the person 

listed in the FOR FURTHER INFORMATION

CONTACT section of this notice. 

Presentation materials must be received 

at the address specified in the 

ADDRESSES section of this notice. 

Deadline for All Other Attendees 

Registration: Individuals may register 

online at http://www.cms.gov/mcd/ 

index_list.asp?list_type=mcac via e-mail 

at MEDCAC_Registration@cms.hhs.gov, 

or by phone by contacting the person 

listed in the FOR FURTHER INFORMATION

CONTACT section of this notice by 5 p.m. 

EST, Wednesday, November 10, 2010. 

We will be broadcasting the meeting via 

Webinar. You must register for the 

Webinar portion of the meeting at 

https://webinar.cms.hhs.gov/_a7/ 

txmetaprostatemedcac1117/event/ 

registration.html by 5 p.m. EST, 

Wednesday, November 10, 2010. 

Deadline for Submitting a Request for 

Special Accommodations: Persons 

attending the meeting who are hearing 

or visually impaired, or have a 

condition that requires special 

assistance or accommodations, are 

asked to contact the Executive Secretary 

as specified in the FOR FURTHER

INFORMATION CONTACT section of this 

notice no later than 5 p.m., EST Friday, 

November 5, 2010. 

ADDRESSES: Meeting Location: The 

meeting will be held in the main 

auditorium of the Centers for Medicare 

& Medicaid Services, 7500 Security 

Boulevard, Baltimore, MD 21244. 

Submission of Presentations and 

Comments: Presentation materials and 

written comments that will be presented 

at the meeting must be submitted via email to 

MedCACpresentations@cms.hhs.gov or 

by regular mail to the contact listed in 

the FOR FURTHER INFORMATION CONTACT

section of this notice by the date 

specified in the DATES section of this 

notice. 

FOR FURTHER INFORMATION CONTACT: 

Maria Ellis, Executive Secretary for 

MEDCAC, Centers for Medicare & 

Medicaid Services, Office of Clinical 

Standards and Quality, Coverage and 

Analysis Group, C1–09–06, 7500 

Security Boulevard, Baltimore, MD 

21244 or contact Ms. Ellis by phone 

(410–786–0309) or via e-mail at 

Maria.Ellis@cms.hhs.gov. 

SUPPLEMENTARY INFORMATION: 

I. Background 

The MEDCAC, formerly known as the 

Medicare Coverage Advisory Committee 

(MCAC), provides advice and 

recommendations to CMS regarding 

clinical issues. (For more information 

on MCAC, see the December 14, 1998 

Federal Register (63 FR 68780).) This 

notice announces the November 17, 

2010, public meeting of the Committee. 

During this meeting, the Committee will 

discuss the currently available evidence 

regarding the clinical benefits and 


srobinson on DSKHWCL6B1PROD with NOTICES